MORE►
Almaden Genomics
David Gascoigne, CEO of Almaden Genomics [Photo: Almaden]
Dallas’ Almaden Genomics Launches New Data Management and Informatics Service Business
by David Seeley | Sep 18, 2024
Almaden—which was formerly part of IBM Research before launching as a standalone company in 2022 under Catalyze Dallas ownership—aims to complement its g.nome workflow platform with the new service business. The goal: providing solutions that streamline data analysis and management in drug discovery, diagnostics, biotech research, and more.
by Lance Murray |
Sep 9, 2024
The innovators will be recognized at the 10th Annual BioNTX iC³ Life Science & Healthcare Innovation Summit. The signature event is set for October 3-4 at the new Loews Arlington Convention Center in Arlington.
MORE►
by Dallas Innovates | Staff Report |
Jan 25, 2024
At the annual Innovation Awards event, Dallas Innovates and D CEO revealed the winners in 17 categories and recognized all 74 North Texas finalists.
MORE►
by Lance Murray |
Jun 9, 2023
Ellen Gordon has worked for more than two decades on behalf of pharmaceutical and biotech companies to deliver insights and much-needed solutions. "Her experience supporting the swift development of novel medicines makes her ideal for helping our clients leverage g.nome to accelerate drug discovery," CEO David Gascogine said.
MORE►
Almaden Genomics Chief Scientific Officer Mark Kunitomi (left) and Almaden's Executive Chairperson Tricia D’Cruz [Photos: Almaden Genomics]
Catalyze Dallas Launches New Portfolio Company to ‘Democratize and Accelerate Bioinformatics’
by Kevin Cummings | Oct 25, 2022
The Dallas-based venture development firm—which specializes in the commercialization of technology it acquires from Fortune 100 companies—has launched Almaden Genomics, a company with a newly released platform designed to streamline genomic workflows. Formerly part of IBM Research before its acquisition by Catalyze Dallas, Almaden calls its g.nome platform "a revolutionary approach to bioinformatics."
“The possibilities for the healthcare innovation it can power are as vast as they are life-changing," says Mark Kunitomi, Almaden's chief scientific officer.
MORE►
